Regeneron(REGN) Prnewswire·2025-02-20 10:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the pricing and sales of Eylea, a primary product of the company [1]. Allegations Summary - The lawsuit claims that Regeneron made materially false and misleading statements by failing to disclose payments made to distributors to cover credit card fees, which affected the pricing of Eylea [1]. - It is alleged that these undisclosed payments led to a price concession that lowered Eylea's selling price, providing a competitive advantage in the market [1]. - The complaint further asserts that Regeneron overstated the average selling price (ASP) reported to federal agencies, violating the False Claims Act, and that positive statements about the company's business were misleading [1]. Class Action Details - The class period for the lawsuit is defined as November 2, 2023, to October 30, 2024, with a deadline for shareholders to register for participation set for March 10, 2025 [2]. - Shareholders who register will receive updates on the case's progress and can seek to be appointed as lead plaintiff without any cost or obligation [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions [3].